No Carolina / NY / Florida
Ph: 561.316.3330

Garvis Raises €3.5 Mil Euros for a Bionic AI Platform to Optimize Supply Chain Management

The London based start-up uses AI for a rapid response to global fluctuations in purchase behavior

Summation

  • The investment in Garvis adds another company in the AI and Software domain to our portfolio of innovative start-ups.
  • Our mission is not only for large companies, but also so small and medium-sized businesses can have access to demand and inventory planning based on AI technology.
  • Poor demand and inventory planning has a huge impact on business results and is extremely wasteful.

A year after the launch of its AI platform for demand and inventory planning, Belgian startup Garvis raised € 3.5 million to develop the platform. Investors include British investment funds Superseed and Scalebridge Capital, and the German group Bosch Ventures. Garvis’ technology enables companies to respond at lightning speed to upheavals and evolutions that influence customer purchase behavior. One unique feature: even non-specialists are able to use the platform within a day.

From sourcing raw materials to manufacturing to customer deliveries: making predictions is essential to business, yet is increasingly difficult to do. The war in Ukraine, skyrocketing inflation, tight labor markets and other global upheavals are making consumer buying behavior harder to anticipate; traditional planning methods for estimating inventory is no longer sufficient. Often consisting of simple Excel spreadsheets, old models make forecasts based on past data—data that is no longer reliable.

Bionic interface

Businesses need a radical new planning method that uses risk profiles, insight and real-time data. The platform Garvis developed, maps relevant environmental factors and provides transparent, explainable insights and predictions of demand patterns for various industries such as automotive, semiconductor, retail, and food and beverage. It uses open-box AI to respond to global fluctuations in buying behavior. Unexpected changes in demand patterns are recognized early, allowing planners to immediately adjust their forecasts and keep schedules up to date. Garvis works with the University of Antwerp (Belgium) to continuously optimize the predictive algorithms. Delaware supports the commercialization of the platform as a partner.

“With Garvis, the planner stays central,” emphasizes founder and CEO Piet Buyck. “The planner communicates directly through Artificial Intelligence with what we call a bionic interface. Thanks to an accumulation of experience, Garvis can automatically convert real-time data into highly accurate plans. Businesses can optimize their inventories, use available materials more efficiently, and ensure better customer service.”

The paradigm shift towards man-machine collaboration results in lower implementation time, less costs, and reduced forecast error.

Fundamental revolution

Though less than a year old, Garvis recently raised € 3.5 million from British investment funds Superseed and Scalebridge Capital, and German group Bosch Ventures. More than 50 established names use the platform today, such as Jacobs Douwe Egberts. With the new capital injection, Garvis aims to further internationalize and democratize the AI platform.

Tineke Kok, Global IBP Manager at Jacobs Douwe Egberts: “Our products are often heavily promoted, so demand can vary widely. It is incredibly difficult to make accurate predictions. We have tested Garvis thoroughly and we are extremely satisfied with the results.”

Piet Buyck: “Usually, multinationals have their own sophisticated planning systems. Our mission is not only for large companies, but also so small and medium-sized businesses can have access to demand and inventory planning based on AI technology. The level of IT maturity is irrelevant. Even non-specialists can start working with our platform in just one day—a revolution in our industry.”

Dan Bowyer, Co-founder and Partner at Superseed: “Weak forecasting causes sales to fluctuate between 2 and 10 percent. Poor demand and inventory planning has a huge impact on business results and is extremely wasteful. Garvis’ solution comes at just the right time. The technology can have a huge impact on business.”

Dr. Ingo Ramesohl, Managing Director of Bosch Ventures: “Garvis is a key enabler to strengthen companies’ resilience of global supply chains through forecast fluctuating sales and working capital needs for companies worldwide. Bosch has started to work with Garvis in several regions. The investment in Garvis adds another company in the AI and Software domain to our portfolio of innovative start-ups.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Enifer Secures €36M In Funding

Enifer, a biotech scaleup is gearing up the production of its PEKILO® mycoprotein with a new €33M factory located in Kirkkonummi, Finland. With already existing collaborations with the world’s leading food and feed companies, Enifer is prepared to annually upcycle food industry side streams into up to 3,000 tons of its sustainable fungi-based protein

Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

Funding will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations reports Phenomix Sciences.

R3 Vascular Announces $87 Million in Series B Financing

R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy